As Biotechnology companies, MeiraGTx Holdings plc (NASDAQ:MGTX) and Adaptimmune Therapeutics plc (NASDAQ:ADAP) are our subject to contrast. And more specifically their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MeiraGTx Holdings plc||20||953.18||N/A||-3.14||0.00|
|Adaptimmune Therapeutics plc||4||4.34||N/A||-1.02||0.00|
Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for MeiraGTx Holdings plc and Adaptimmune Therapeutics plc.
Table 2 has MeiraGTx Holdings plc and Adaptimmune Therapeutics plc’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|MeiraGTx Holdings plc||0.00%||-79.6%||-59.3%|
|Adaptimmune Therapeutics plc||0.00%||-45%||-38.3%|
The Current Ratio and Quick Ratio of MeiraGTx Holdings plc are 7 and 7 respectively. Its competitor Adaptimmune Therapeutics plc’s Current Ratio is 8.5 and its Quick Ratio is 8.5. Adaptimmune Therapeutics plc can pay off short and long-term obligations better than MeiraGTx Holdings plc.
The following table shown below contains the ratings and recommendations for MeiraGTx Holdings plc and Adaptimmune Therapeutics plc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|MeiraGTx Holdings plc||0||0||0||0.00|
|Adaptimmune Therapeutics plc||0||0||2||3.00|
Competitively the average target price of Adaptimmune Therapeutics plc is $7.5, which is potential 328.57% upside.
Institutional & Insider Ownership
Roughly 36.6% of MeiraGTx Holdings plc shares are held by institutional investors while 73.4% of Adaptimmune Therapeutics plc are owned by institutional investors. Insiders held 19.39% of MeiraGTx Holdings plc shares. On the other hand, insiders held about 0.22% of Adaptimmune Therapeutics plc’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|MeiraGTx Holdings plc||-5.9%||-2.92%||46.43%||185.64%||211.43%||182.68%|
|Adaptimmune Therapeutics plc||-0.6%||-9.86%||-31.6%||-29.4%||-65.11%||-42.78%|
For the past year MeiraGTx Holdings plc has 182.68% stronger performance while Adaptimmune Therapeutics plc has -42.78% weaker performance.
Adaptimmune Therapeutics plc beats on 5 of the 8 factors MeiraGTx Holdings plc.
MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma. It is also developing MAGE A-10 peptide that is in Phase I/II clinical trials to treat urothelial (bladder), melanoma, and head and neck cancers, as well as NSCLC; AFP SPEAR T-cell therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma; and MAGE-A4 to treat urothelial (bladder), melanoma, head and neck, esophageal and gastric, and ovarian cancer, as well as NSCLC. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a collaboration agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.